Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells

Fig. 5

Pladienolide B impairs pre-mRNA splicing and increases the sensitivity of cancer cells to cisplatin. a Viability assay of SKOV3, A549, HepG2, and HT29 cells that were pretreated with 2 nM pladienolide B (2 days) following treatment with different concentrations of cisplatin (4 days). b FACS analysis of caspase 3/7 and SYTOX staining of A549 cells treated with 0.5 nM pladienolide B, 10 μM Cisplatin or both drugs together. c FACS analysis of phospho ATM staining of SKOV3 cells that were cultivated with different concentrations of pladienolide B (2 days) and subsequently treated with 10 μM Cisplatin (1 day). d Representative immunofluorescence images of SKOV3 cells stained for phosphoATM (S1981) (green) and with DAPI (blue) after treatment with 10 μM Cisplatin in the presence or absence of 0.5 nM Pladienolide B. Scale bar: 50 μm. e Enrichment analysis of genes affected by differential splicing events before and after treatment with splicing inhibitors: pladienolide B (upper part; E-GEOD-67770) and spliceostatin A (lower part; GSE72156). The STRING database was used for Gene Ontology Biological Processes analysis

Back to article page